Provectus News Provectus Biopharmaceuticals Re
Post# of 23086
Posted On: 06/02/2015 8:33:36 AM
Provectus News
Provectus Biopharmaceuticals Retains Allison+Partners as New Media Relations Consultant
Tuesday June 2, 2015
KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Biopharmaceuticals, Inc. (NYSE MKT: PVCT, www.pvct.com), a clinical-stage oncology and dermatology biopharmaceutical company ("Provectus" or the "Company"
, announced today that it has retained Allison+Partners as its new media relations consultant.
Peter Culpepper, CFO and COO of Provectus, said, "We are very happy to have retained Allison+Partners to take over our media relations efforts. As our pivotal phase 3 clinical trial of PV-10 as a treatment for melanoma gets underway, we believe that we have to devote greater resources to our contact with the public by way of the media. With PhRMA, the Pharmaceutical Research and Manufacturers of America, on its roster of clients, we are confident that Allison+Partners understands our communications needs and has the contacts and resources to raise our profile even higher.
Matthew Della Croce, President, Europe and Global Corporate for Allison+Partners, said, "Allison+Partners is very happy to add Provectus Biopharmaceuticals to its client list. It's an exciting time in the development of PV-10, and we are happy to help the company and its management."
The complete press release is available at www.pvct.com/pressrelease.html?article=20140602.1 on the Provectus website.
Provectus Biopharmaceuticals Retains Allison+Partners as New Media Relations Consultant
Tuesday June 2, 2015
KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Biopharmaceuticals, Inc. (NYSE MKT: PVCT, www.pvct.com), a clinical-stage oncology and dermatology biopharmaceutical company ("Provectus" or the "Company"
, announced today that it has retained Allison+Partners as its new media relations consultant. Peter Culpepper, CFO and COO of Provectus, said, "We are very happy to have retained Allison+Partners to take over our media relations efforts. As our pivotal phase 3 clinical trial of PV-10 as a treatment for melanoma gets underway, we believe that we have to devote greater resources to our contact with the public by way of the media. With PhRMA, the Pharmaceutical Research and Manufacturers of America, on its roster of clients, we are confident that Allison+Partners understands our communications needs and has the contacts and resources to raise our profile even higher.
Matthew Della Croce, President, Europe and Global Corporate for Allison+Partners, said, "Allison+Partners is very happy to add Provectus Biopharmaceuticals to its client list. It's an exciting time in the development of PV-10, and we are happy to help the company and its management."
The complete press release is available at www.pvct.com/pressrelease.html?article=20140602.1 on the Provectus website.
(0)
(0)
I'm in it to win it!
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'